← Calendar
Readoutin 135d
Novartis Pharmaceuticals — Ianalumab
Phase 3 primary completion: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1).
- Date
- Apr 2027
- Type
- Readout
- Indication
- Systemic Lupus Erythematosus
Source ↗Add to calendar
Date history
Mar 1, 2027 → Apr 1, 2027Nov 17, 2026
Apr 1, 2027 → Mar 1, 2027Nov 17, 2026
Mar 1, 2027 → Apr 1, 2027Nov 17, 2026
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Novartis Pharmaceuticals
May2027
Readoutin 165d
Novartis Pharmaceuticals — Inclisiran sodium 300 mgPhase 3 primary completion: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease.
Mar2027
Readoutin 104d
Novartis Pharmaceuticals — IanalumabPhase 3 primary completion: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1).
Feb2027
Readoutin 76d
Novartis Pharmaceuticals — everolimusPhase 3 primary completion: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment.